



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Schneck and O'Herrin) GAU: 1642
Serial No.: 09/642,660) Examiner: Christopher H. Yaen
Filed: August 22, 2000) Docket No. 001107.00042

For: **CELL COMPOSITIONS COMPRISING MOLECULAR COMPLEXES
THAT MODIFY IMMUNE RESPONSES**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, enclosed is a PTO Form-1449 listing documents for consideration by the Examiner during the prosecution of the subject application.

Please charge our Deposit Account No. 19-0733 in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for the filing fee.

Respectfully submitted,

Dated: July 20, 2006

By: Lisa M. Hemmendinger
Lisa M. Hemmendinger
Registration No. 42,653

Customer No. 22907

07/24/2006 HALI11 00000054 190733 09042660
01 FC:1806 180.00 DA



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/642,660
Filing Date	August 22, 2000
First Named Inventor	Schneck
Group Art Unit	1643
Examiner Name	Christopher H. Yaen
Attorney Docket Number	001107.00042

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Deeths et al., "B7-1-Dependent co-stimulation results in qualitatively and quantitatively different responses by CD4 ⁺ and CD8 ⁺ T cells", European Journal of Immunology, Vol. 27, No. 3, 1997, pp 598-608.	
		OERTLI et al., "Artificial antigen-presenting cells engineered by recombinant vaccinia viruses expressing antigen, MHC class II, and costimulatory molecules elicit proliferation of CD4 ⁺ lymphocytes invitro", Clinical and Experimental Immunology, Vol. 110, No. 1, October 1997, pp 144-149.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.